These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20118960)

  • 1. Ofatumumab.
    Keating MJ; Dritselis A; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Feb; 9(2):101-2. PubMed ID: 20118960
    [No Abstract]   [Full Text] [Related]  

  • 2. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
    Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ofatumumab (Arzerra) for CLL.
    Med Lett Drugs Ther; 2010 Jun; 52(1341):51-2. PubMed ID: 20585286
    [No Abstract]   [Full Text] [Related]  

  • 5. Ofatumumab approved for advanced CLL.
    Traynor K
    Am J Health Syst Pharm; 2009 Dec; 66(23):2062. PubMed ID: 19923303
    [No Abstract]   [Full Text] [Related]  

  • 6. Ofatumumab for the treatment of chronic lymphocytic leukemia.
    Grosicki S
    Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
    Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
    Nightingale G
    Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
    Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
    J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological profile of human-type anti-CD20 antibody ofatumumab (Arzerra(®)) and its clinical study results].
    Yoshizaki H; Tomonari A
    Nihon Yakurigaku Zasshi; 2014 Jan; 143(1):40-3. PubMed ID: 24420136
    [No Abstract]   [Full Text] [Related]  

  • 11. Ofatumumab.
    Sanford M; McCormack PL
    Drugs; 2010 May; 70(8):1013-9. PubMed ID: 20481657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community-based phase II trial of PCR for CLL/SLL patients.
    Kay NE; Shanafelt TD; Byrd JC; Grever MR
    Cancer Biother Radiopharm; 2007 Oct; 22(5):713-4; author reply 715-7. PubMed ID: 17979574
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
    Coiffier B; Lepretre S; Pedersen LM; Gadeberg O; Fredriksen H; van Oers MH; Wooldridge J; Kloczko J; Holowiecki J; Hellmann A; Walewski J; Flensburg M; Petersen J; Robak T
    Blood; 2008 Feb; 111(3):1094-100. PubMed ID: 18003886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
    J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berlex Laboratories to market new treatment for B-CLL.
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):3. PubMed ID: 12113127
    [No Abstract]   [Full Text] [Related]  

  • 16. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
    Korycka-Wołowiec A; Wołowiec D; Robak T
    Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
    O'Brien S; Osterborg A
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):361-8. PubMed ID: 21030349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
    Thompson CA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
    [No Abstract]   [Full Text] [Related]  

  • 20. Obinutuzumab: first global approval.
    Cameron F; McCormack PL
    Drugs; 2014 Jan; 74(1):147-54. PubMed ID: 24338113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.